Ironwood Pharmaceuticals Inc (IRWD)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $799.61M
Last updated: Nov 17, 2026 at 11:06 AM ET
Ironwood Pharmaceuticals Inc (IRWD) P/E Ratio & Valuation History
Ironwood Pharmaceuticals (IRWD) trades at 5.4x trailing earnings and 2.0x sales. Its P/S of 2.0x is below its 5-year median of 2.8x. Its forward P/E is 12.3x. The median P/E across 9 similar companies is 12.7x.
Current Multiples
Its forward P/E is above its trailing P/E, which implies earnings per share about 56.1% lower over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 5.4x |
| Forward P/E | 12.3x |
| Price to sales | 2.0x |
| EV/EBITDA | 4.1x |
| PEG | N/A |
Historical Medians
Against its 10-year medians, its P/S is 53.5% below 4.3x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 2.0x | 2.8x | 4.3x |
Valuation History
Over the 6 of the 10 year ends shown that have a P/E, its P/E ranged from 9.9x in 2021 to 303.4x in 2024.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $3.37 | 14.7x | 1.9x | N/A |
| 2024 | $4.43 | 303.4x | 2.0x | N/A |
| 2023 | $11.44 | N/A | 4.0x | N/A |
| 2022 | $12.39 | 12.8x | 4.9x | 3.5x |
| 2021 | $11.66 | 9.9x | 4.6x | 3.2x |
| 2020 | $11.39 | 14.4x | 4.7x | 29.4x |
| 2019 | $13.31 | 24.6x | 4.9x | N/A |
| 2018 | $10.36 | N/A | 4.6x | N/A |
| 2017 | $14.99 | N/A | 7.5x | 228.1x |
| 2016 | $15.29 | N/A | 8.2x | 34.4x |
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRWD
What is IRWD's forward P/E ratio?
Ironwood Pharmaceuticals has a forward P/E ratio of 12.3x.
Is IRWD stock overvalued?
GNG's valuation label for IRWD is Undervalued. Its P/E of 5.4x compares with a median of 12.7x across 9 similar companies.
What is IRWD's price to sales ratio?
Ironwood Pharmaceuticals has a price to sales ratio of 2.0x.
IRWD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors